Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Five scenarios for the future of Antarctic life
A team of Australian and international researchers have predicted five possible outcomes for how...
Could this biosensor bypass labs with onsite PFAS detection?
La Trobe University has developed a portable biosensor that may allow rapid, onsite detection of...
How a tiny worm changed a decade of scientific thinking
A tiny roundworm has helped University of Queensland scientists rethink the way sensory nerve...
